Angela Shen
InvestorSenior Advisor at Quan Capital
About
Dr. Angela Shen is a Senior Advisor at Quan Capital and Vice President of Strategic Innovation Leaders at Mass General Brigham, where she works on translational medicine, clinical development, and regulatory affairs with a focus on gene and cell therapy. She previously served as Chief Medical Officer at biotech companies including Arcellx, NKarta, and Arvinas, acting CMO at Tizona, and held oncology drug development roles at Novartis, Exelixis, and Johnson & Johnson. At Novartis she led the clinical team behind the first multi-site registration CAR-T trial, resulting in the approval of Kymriah. She holds a BS from Rensselaer, an MD from Albany Medical College, and an MBA from NYU Stern.
Invests in
BiotechHealthtechMedical Devices
Colleagues at Quan Capital
Frequently asked questions
- Who is Angela Shen?
- Dr. Angela Shen is a Senior Advisor at Quan Capital and Vice President of Strategic Innovation Leaders at Mass General Brigham, where she works on translational medicine, clinical development, and regulatory affairs with a focus on gene and cell therapy. She previously served as Chief Medical Officer at biotech companies including Arcellx, NKarta, and Arvinas, acting CMO at Tizona, and held oncology drug development roles at Novartis, Exelixis, and Johnson & Johnson. At Novartis she led the clinical team behind the first multi-site registration CAR-T trial, resulting in the approval of Kymriah. She holds a BS from Rensselaer, an MD from Albany Medical College, and an MBA from NYU Stern.
- Where does Angela Shen work?
- Angela Shen is Senior Advisor at Quan Capital.
- What does Angela Shen invest in?
- Angela Shen invests in Biotech, Healthtech, Medical Devices.